Skip to main content

Paul Langlie Martin, MD, PhD

Professor of Pediatrics
Chief, Division of Pediatric Blood and Marrow Transplantation
Member of the Duke Cancer Institute
Campus mail: 1400 Morrene Rd, Durham, NC 27705
Phone: (919) 668-1124
Email address:

For most of my career in Pediatric Hematology/Oncology I have focused on the use of stem cell transplant for the treatment of pediatric leukemias (ALL, AML, CML and JMML) and other non-malignant blood disorders, such as thalassemia, hemaphagocytic disorders, Wiskott-Aldrich, aplastic anemia, Diamond-Blackfan Anemia, as well as inherited metabolic diseases. In addition to focusing on determining the best use of stem cell transplants for these disorders, I have also been involved in clinical research investigating the prevention and treatment of transplant related morbidity, particularly veno-occlusive disease of the liver, infections and diffuse alveolar hemorrhage. As study chair for the Children's Oncology Group protocol 9904, I was involved in the development, implementation and analysis of a large, international frontline study of childhood acute lymphoblastic leukemia. Results from this study show that a significant number of children with certain favorable cytogenetic abnormalities in their leukemic cells and who have a rapid response to their initial chemotherapy can expect to have a >95% chance of cure when treated with relatively low intensity chemotherapy.  

For most of my time at Duke I have concentrated on providing high quality care for high risk leukemia patients who require high intensity therapies, such as stem cell transplant and immunotherapy.  As a member of the Pediatric Transplant and Cellular Therapy Division I provide clinical care for these patients.  As a member of various cooperative groups and local PI for several drug trials, I have worked to provide better care and more specific therapies for the toxicities associated with stem cell transplant.  

I have also collaborated with the Pediatric Immunology Division to provide a life-saving therapy for a small group of patients with thymic dysfunction, which causes severe immunodeficiency.  Our clinical team now provides support during these patients hospital admissions for donor thymus tissue implantation.

Education and Training

  • Fellow, Pediatric Hematology/Oncology, Pediatrics, Yale University, 1989 - 1992
  • Resident, Pediatrics, Yale University, 1988 - 1989
  • Intern, Pediatrics, Yale University, 1987 - 1988
  • Ph.D., Washington University in St. Louis, 1987
  • M.D., Washington University in St. Louis, 1987


Lund, Troy C., Kwang Woo Ahn, Heather R. Tecca, Megan V. Hilgers, Hisham Abdel-Azim, Allistair Abraham, Miguel Angel Diaz, et al. “Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia.” Biol Blood Marrow Transplant 25, no. 2 (February 2019): 301–6.

Full Text

Mahadeo, Kris M., Sajad J. Khazal, Hisham Abdel-Azim, Julie C. Fitzgerald, Agne Taraseviciute, Catherine M. Bollard, Priti Tewari, et al. “Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy.” Nat Rev Clin Oncol 16, no. 1 (January 2019): 45–63.

Full Text

Huang, Sihong, Paul Martin, and M Jay Campbell. “Coronary artery occlusion secondary to graft versus host disease after bone marrow transplant in a 21-year-old.” Cardiol Young 28, no. 12 (December 2018): 1484–86.

Full Text

Grupp, Stephan A., Shannon L. Maude, Susana Rives, Andre Baruchel, Michael W. Boyer, Henrique Bittencourt, Peter Bader, et al. “Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia.” In Blood, 132:895–895. American Society of Hematology, 2018.

Full Text

Duncan, Christine N., Ruta Brazauskas, Jiaxing Huang, Bronwen E. Shaw, Navneet S. Majhail, Bipin N. Savani, Mary E. D. Flowers, et al. “Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation.” Bone Marrow Transplant 53, no. 10 (October 2018): 1278–87.

Full Text

Jacobsohn, David A., Michael R. Loken, Mingwei Fei, Alexia Adams, Lisa Eidenschink Brodersen, Brent R. Logan, Kwang Woo Ahn, et al. “Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression.” Biol Blood Marrow Transplant 24, no. 10 (October 2018): 2040–46.

Full Text

Kelly, Matthew S., Lisa Spees, Richard Vinesett, Andre Stokhuyzen, Lauren McGill, Alan D. Proia, Kirsten Jenkins, Mehreen Arshad, Patrick C. Seed, and Paul L. Martin. “Utility of Autopsy among Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients: One Last Chance to Learn?” Biol Blood Marrow Transplant 24, no. 9 (September 2018): 1861–65.

Full Text

Churchman, Michelle L., Maoxiang Qian, Geertruy Te Kronnie, Ranran Zhang, Wenjian Yang, Hui Zhang, Tobia Lana, et al. “Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia.” In Cancer Cell, 33:937-948.e8, 2018.

Full Text

Parikh, Suhag, Joel A. Brochstein, Stephen Wease, Paul L. Martin, Mitchell E. Horwitz, Aurelie Schwarzbach, and Joanne Kurtzberg. “A Novel Therapy for Sickle Cell Disease (SCD): Co-Transplantation of Nicord (R) [Ex Vivo Expanded Umbilical Cord Blood (UCB) Progenitor Cells with Nicotinamide] and an Unmanipulated Unrelated UCB Graft Leads to Successful Engraftment and Cure of Severe SCD.” In Biology of Blood and Marrow Transplantation, 24:S157–58. ELSEVIER SCIENCE INC, 2018.


Qian, Maoxiang, Xueyuan Cao, Meenakshi Devidas, Wenjian Yang, Cheng Cheng, Yunfeng Dai, Andrew Carroll, et al. “TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.” J Clin Oncol 36, no. 6 (February 20, 2018): 591–99.

Full Text